Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021159050 - COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION

Publication Number WO/2021/159050
Publication Date 12.08.2021
International Application No. PCT/US2021/017006
International Filing Date 08.02.2021
IPC
A61K 31/7048 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7048having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 36/24 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
24Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/727
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
727Heparin; Heparan
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/0078
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
007Pulmonary tract; Aromatherapy
0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy;
0078for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • HEPALINK USA INC. [US]/[US]
  • SHI, Yuenian [US]/[US]
  • LI, Li [CN]/[CN]
  • LI, JinPing [SE]/[SE]
Inventors
  • SHI, Yuenian
  • LI, Li
  • LI, JinPing
Agents
  • ZHENG, Lihua
Priority Data
62/972,02809.02.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION
(FR) COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'INFECTION À CORONAVIRUS
Abstract
(EN) Disclosed are low molecular weight heparins, particularly enoxaparin and their use in the treatment of coronavirus infection, in particular 2019-nCov, in a subject. These low molecular weight heparins may be administered to the subject together with another therapeutic agent such as a corticosteroid, an anti-inflammatory signal transduction modulator, a B2-adrenoreceptor agonist bronchodilator, an anticholinergic, a mucolytic agent, hypertonic saline, imatinib mesylate, nilotinib hydrochlorine, dasatinib, interferon, ribavirin, adefovir, tenofovir, acyclovir, brivudine, cidofovir, fomivirsen, foscarnet, ganciclovir, penciclovir, amantadine, rimantadine, zanamivir and remdesivir.
(FR) Des héparines de faible poids moléculaire, en particulier de l'énoxaparine et leur utilisation dans le traitement d'une infection à coronavirus, en particulier 2019-nCov, chez un sujet sont divulguées. Ces héparines de faible poids moléculaire peuvent être administrées au sujet conjointement à un autre agent thérapeutique tel qu'un corticostéroïde, un modulateur de transduction de signal anti-inflammatoire, un bronchodilatateur agoniste des récepteurs bêta-2 adrénergiques, un anticholinergique, un agent mucolytique, une solution saline hypertonique, du mésylate d'imatinib, du chlorhydrate de nilotinib, du dasatinib, un interféron, de la ribavirine, de l'adéfovir, du ténofovir, de l'acyclovir, de la brivudine, du cidofovir, du fomivirsen, du foscarnet, du ganciclovir, du penciclovir, de l'amantadine, de la rimantadine, du zanamivir et du remdesivir.
Latest bibliographic data on file with the International Bureau